FOLFOX-HAIC为基础的肝细胞癌辅助转化治疗的应用进展

Progress in the application of FOLFOX-HAIC-based adjuvant translational therapy for hepatocellular carcinoma

原发性肝癌是我国最常见的恶性肿瘤之一。手术切除是使肝癌患者获得长期生存乃至治愈的重要手段,但术后复发率高,多数患者初诊时已处于中晚期,不适合手术切除,如何改善肝癌患者预后成了亟待解决的难题。近年来,FOLFOX方案的肝动脉灌注化疗(FOLFOX-HAIC)为基础的肝癌转化治疗及新辅助治疗提高了肝癌患者的生存获益。为厘清FOLFOX-HAIC为基础的肝细胞癌转化治疗与新辅助治疗的作用,本文将对FOLFOX-HAIC为基础的肝细胞癌术前治疗的应用及研究进展进行综述,并探讨FOLFOX-HAIC为基础的肝细胞癌新辅助治疗的潜在优势。

Primary liver cancer is one of the most common malignant tumours in China.Surgical resection is important to achieve long-term survival and even cure for liver cancer patients,but the postoperative recurrence rate is high.Most of the patients are already in the middle or late stage at the time of initial diagnosis and are not suitable for surgical resection,so how to improve the prognosis of liver cancer patients has become a difficult problem that needs to be solved urgently.In recent years,FOLFOX regimen of hepatic arterial infusion chemotherapy(FOLFOX-HAIC)-based conversion and neoadjuvant therapy for hepatocellular carcinoma has improved the survival benefit of hepatocellular carcinoma patients.To clarify the roles of FOLFOX-HAIC-based conversion therapy and neoadjuvant therapy for hepatocellular carcinoma,this article provides a systematic review of the application and research progress of FOLFOX-HAIC-based preoperative therapy for hepatocellular carcinoma and discusses the potential advantages of FOLFOX-HAIC-based neoadjuvant therapy for hepatocellular carcinoma.